

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 January 2025 (16.01.2025)



(10) International Publication Number
WO 2025/015320 A3

(51) International Patent Classification:

C07K 16/28 (2006.01) C07K 16/40 (2006.01)
A61P 35/00 (2006.01) A61P 35/04 (2006.01)

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2024/037940

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(22) International Filing Date:

12 July 2024 (12.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(88) Date of publication of the international search report:

13 February 2025 (13.02.2025)

(30) Priority Data:

63/526,444 12 July 2023 (12.07.2023) US

(71) Applicant: PHENOMIC AI [CA/CA]; 661 University Avenue, Suite 1300, Mars Centre, West Tower, Toronto, ON M5G 0B7 (CA).

(72) Inventors; and

(71) Applicants: HARVEY, Christopher [US/US]; C/o Phenomic AI, 661 University Avenue, Suite 1300, Mars Centre West Tower, Toronto, ON M5G 0B7 (CA). LONDON, Max [CA/CA]; C/o Phenomic AI, 661 University Avenue, Suite 1300, Mars Centre, West Tower, Toronto, ON M5G 0B7 (CA). BRISKIN, Michael [US/US]; C/o Phenomic AI, 661 University Avenue, Suite 1300, Mars Centre, West Tower, Toronto, ON M5G 0B7 (CA). SUSLOV, Nikolai [CA/CA]; C/o Phenomic AI, 661 University Avenue, Suite 1300, Mars Centre, West Tower, Toronto, ON M5G 0B7 (CA).

(74) Agent: LORENZ, Todd et al.; Squire Patton Boggs, 555 California Street, Suite 550, San Francisco, CA 94104 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: ANTI-CTHRC1 T CELL ENGAGERS AND METHODS OF USING THE SAME

(57) Abstract: The present invention is directed to anti-CTHRC1 T-cell engagers, compositions comprising the same, and methods of using such anti-CTHRC1 T-cell engagers and compositions for the prevention and/or treatment of cancer.

WO 2025/015320 A3